Gracell Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Gracell Biotechnologies has a total shareholder equity of CN¥1.6B and total debt of CN¥103.1M, which brings its debt-to-equity ratio to 6.4%. Its total assets and total liabilities are CN¥1.9B and CN¥268.9M respectively.
Key information
6.4%
Debt to equity ratio
CN¥103.15m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.71b |
| Equity | CN¥1.62b |
| Total liabilities | CN¥268.86m |
| Total assets | CN¥1.89b |
Recent financial health updates
Recent updates
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Feb 21Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform
Sep 22Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02
Aug 15Gracell Biotechnologies rallies after naming new chief medical officer
Aug 01Gracell names Dr. Samuel Zhang as Chief Business Officer
Jul 19Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Nov 26Gracell ends IPO quiet period with favorable views from analysts
Feb 02Financial Position Analysis
Short Term Liabilities: GRCL's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥229.5M).
Long Term Liabilities: GRCL's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥39.4M).
Debt to Equity History and Analysis
Debt Level: GRCL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GRCL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRCL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GRCL has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 33.3% each year.